60 Degrees Pharmaceuticals, Inc. SXTP 深 沪
等待开盘 10-13 09:30:00 美东时间
0.9156
-0.050
-5.16%
华盛通- 最 高0.9627
- 今 开0.9386
- 成交量 3.82万股
- 最 低 0.8909
- 昨 收 0.9654
- 总市值 322.02万
- 52周最高 8.62
- 市盈率 静 --
- 换手率 1.09%
- 52周最低 0.84
- 委 比 97.99%
- 总股本 351.70万
- 历史最高 2076.00
- 量 比 0.06
- 振 幅 7.44%
- 历史最低 0.8909
- 每 手 1
- 风险率 1.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多60 Degrees Pharmaceuticals Stock Falls 6% in Pre-Market Ahead of Tafenoquine Trial Interim Results: What Investors Are Watching Tuesday?
60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) shares fell about 6.22% to $1.35 in the pre-market session on Tuesday ahead of interim results from a trial of tafenoquine in patients hospitalized with severe babesiosis. On Monday, the Washington-based pharmaceutical company’s stock closed at $1.44, up...
10-06 17:02
60 Degrees Q2 EPS $(0.90) Misses $(0.86) Estimate, Sales $56.798K Miss $186.000K Estimate
60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.86) by 4.65 percent. This is a 82.04 percent increase over losses of $(5.01) per share from the same period last year. The company reported quarterly sales of $56.798 thousand w...
08-15 03:48
60 Degrees Pharmaceuticals Announces $1M Private Placement Of 574,713 Shares At $1.74, Including Warrants
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 574,7...
07-31 02:26
60 Degrees Pharma's B-Free Babesiosis Trial Clears Initial Safety Review, Advances After DSMB Recommendation
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chronic ...
07-01 20:08
60 Degrees Pharma Executes Patent Licensing Agreement With Florida State University To Commence Large-Scale Production Techniques To Extract, Purify Castanospermine From Seeds Of Australian Chestnut For Non-Prescription Uses
License allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company's recent New Dietary Ingredient Notification (NDIN) to...
06-11 20:13
60 Degrees Pharmaceuticals Says Co. May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001946563/000121390026064796/ea0293532-8k_60degrees.htm
06-04 05:08
Ascendiant Capital Maintains Buy on 60 Degrees, Lowers Price Target to $3.7
Ascendiant Capital analyst Lucas Ward maintains 60 Degrees (NASDAQ:SXTP) with a Buy and lowers the price target from $4.2 to $3.7.
05-22 19:56
HC Wainwright & Co. Downgrades 60 Degrees to Neutral
HC Wainwright & Co. analyst Matthew Keller downgrades 60 Degrees (NASDAQ:SXTP) from Buy to Neutral.
05-21 01:03
60 Degrees Q1 EPS $(1.28) Misses $(0.76) Estimate, Sales $76.377K Miss $435.000K Estimate
60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0.76) by 68.42 percent. This is a 79.52 percent increase over losses of $(6.25) per share from the
05-15 21:29
美股大行评级 | 小摩上调Lumentum控股目标价从565美元升至950美元；大小摩齐上调美国铝业目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13美元升至13.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8.25美元升至9美元
04-10 18:27
